ArticleCurrent urology2022
Prostate cancer screening: Continued controversies and novel biomarker advancements.
Article in Current urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Fluorescent bionanosensor for picomolar detection of biomarkers in fluids.European biophysics journal : EBJ · 2026Article
- Comprehensive biochemical insights into derivatives of PSA and glycosylation-specific changes in PSA: role in diagnosis and management of prostate cancer.Clinical proteomics · 2026Review
- Association between the G-protein-coupled estrogen receptor 1 and prostate cancer in the Slovak population.Molecular biology reports · 2026Article
- Targeting prostate adenocarcinoma tumor microenvironment via cancer nanotheranostics: a comprehensive update on improved roadmap for disease diagnosis, therapy and management.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Beyond the Usual Suspects: Emerging Associations Between Epstein-Barr Virus Infection/Infectious Mononucleosis and Cancers.Reviews in medical virology · 2026Review
- From prostate specific antigen to genomic signatures: Advances in biomarkers for prostate cancer diagnosis and prognosis.Translational oncology · 2026Review
- Diagnostic accuracy of prostate-specific antigen and prostate-specific antigen density in patients suspected of having prostate cancer in South Korea: A large, multi-institutional registry.Investigative and clinical urology · 2026Article
- Article
- Prostate specific antigen retesting intervals and trends in England: population based cohort study.BMJ (Clinical research ed.) · 2025Article
- Lessons from the implementation of the Australian 2016 prostate specific antigen testing clinical practice guidelines: a descriptive study.ANZ journal of surgery · 2025Article
- Possible Roles for Purinergic Receptor P2RX4 in Breast and Prostate Cancers.International journal of molecular sciences · 2025Review
- Research protocol for the evaluation of TriNetra™ prostate: a circulating tumor cell-based diagnostic tool for prostate cancer.International journal of surgery protocols · 2025Article
- Early Activation of a Multilevel Prostate Cancer Screening Model: Pilot Phase Results and Strategic Perspectives in Lombardy Region.Healthcare (Basel, Switzerland) · 2025Article
- Electrochemical Detection of Prostate Cancer-Associated miRNA-141 Using a Low-Cost Disposable Biosensor.Biosensors · 2025Article
- NEIL3 promotes the carcinogenesis of prostate cancer by activating PI3K/Akt/mTOR signaling.Discover oncology · 2025Article
- Next-Gen Point-of-Care Tool for Ultra-Sensitive Detection of Urinary Spermine for Prostate Cancer Diagnosis.ACS sensors · 2025Article
- Utilization of artificial intelligence in prostate cancer detection: a comprehensive review of innovations in screening and diagnosis.Frontiers in immunology · 2025Review
- Risk-stratified Approach to Implementing Population-based Prostate Cancer Screening in Five Pilot Sites in the European Union: A Protocol for the PRAISE-U Project.European urology open science · 2024Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) screening remains one of the most controversial topics in clinical and public health. Despite being the second most common cancer in men worldwide, recommendations for screening using prostate-specific antigen (PSA) are unclear. Early detection and the resulting postscreening treatment lead to overdiagnosis and overtreatment of otherwise indolent cases. In addition, several unwanted harms are associated with PCa screening process. This literature review focuses on the limitations of PSA-specific PCa screening, reasons behind the screening controversy, and the novel biomarkers and advanced innovative methodologies that improve the limitations of traditional screening using PSA. With the verdict of whether or not to screen not yet unanimous, we hope to aid in resolution of the long-standing debate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.